You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Thermo will develop a test using its Oncomine Precision Assay to identify IDH1- and IDH2-positive low-grade glioma patients for treatment with Agios' vorasidenib.
The company is working with German informatics firm MSAID to incorporate deep learning into mass spec analysis and with Biognosys on tools for quantitative work.
Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.
Wadsworth's test detects antibodies against SARS-CoV-2 in serum, while Altru Diagnostics' test detects viral nucleic acid in respiratory specimens.
The test is a modified version of Thermo Fisher Scientific's TaqPath COVID-19 SARS-CoV-2 Test, which received Emergency Use Authorization last month.
The company had announced on March 3 that the lenders had committed to the debt financing in connection with its proposed acquisition of Qiagen.
The study, which is being supported by Thermo Fisher Scientific, aims to identify genetic biomarkers that can predict patients likely to develop severe disease.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.